Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
0.9650
Dollar change
-0.0550
Percentage change
-5.39
%
Index- P/E- EPS (ttm)-0.19 Insider Own- Shs Outstand145.72M Perf Week25.32%
Market Cap140.62M Forward P/E- EPS next Y- Insider Trans- Shs Float22.85M Perf Month17.68%
Income-9.09M PEG- EPS next Q- Inst Own0.14% Short Float0.06% Perf Quarter2.32%
Sales2.42M P/S58.11 EPS this Y- Inst Trans-13.33% Short Ratio0.76 Perf Half Y30.05%
Book/sh0.95 P/B1.02 EPS next Y- ROA-11.19% Short Interest0.01M Perf Year69.28%
Cash/sh0.58 P/C1.65 EPS next 5Y- ROE-12.36% 52W Range0.53 - 2.90 Perf YTD30.41%
Dividend Est.- P/FCF103.40 EPS past 5Y- ROI-6.57% 52W High-66.72% Beta0.11
Dividend TTM- Quick Ratio- Sales past 5Y23.33% Gross Margin5.16% 52W Low82.08% ATR (14)0.13
Dividend Ex-DateAug 01, 2018 Current Ratio- EPS Y/Y TTM-214.54% Oper. Margin-357.61% RSI (14)53.48 Volatility23.10% 15.82%
Employees9 Debt/Eq0.00 Sales Y/Y TTM-81.66% Profit Margin-375.06% Recom- Target Price4.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q40.33% Payout- Rel Volume0.22 Prev Close1.02
Sales Surprise-7.88% EPS Surprise350.00% Sales Q/Q25.47% Earnings- Avg Volume18.52K Price0.96
SMA209.74% SMA503.64% SMA200-1.77% Trades Volume4,036 Change-5.39%
Akso Health Group operates a social e-commerce platform principally in China that collaborates with other domestic e-commerce platforms and offers users a wide selection of products. It also plans to develop a new business as a cancer therapy and radiotherapy oncology service provider with operations in the U.S. The firm plans to open 2 vaccine research centers and 100 radiation oncology centers to be located on the east coast serving cancer patients in need of varying stages of treatment, including specialized radiation therapy centers for radiotherapy, personalized consultation, conventional treatment planning, and other cancer related treatment services. The company was founded by Xiaobo An in March 2014 and is headquartered in Qingdao, China.